BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yu J, Zhou Z, Tay-sontheimer J, Levy RH, Ragueneau-majlessi I. Intestinal Drug Interactions Mediated by OATPs: A Systematic Review of Preclinical and Clinical Findings. Journal of Pharmaceutical Sciences 2017;106:2312-25. [DOI: 10.1016/j.xphs.2017.04.004] [Cited by in Crossref: 77] [Cited by in F6Publishing: 77] [Article Influence: 15.4] [Reference Citation Analysis]
Number Citing Articles
1 Jin Y, Li Y, Eisenmann ED, Figg WD, Baker SD, Sparreboom A, Hu S. Determination of the endogenous OATP1B biomarkers glycochenodeoxycholate-3-sulfate and chenodeoxycholate-24-glucuronide in human and mouse plasma by a validated UHPLC-MS/MS method. J Chromatogr B Analyt Technol Biomed Life Sci 2022;1210:123437. [PMID: 36054985 DOI: 10.1016/j.jchromb.2022.123437] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Turco L, Santori N, Buratti FM, Dorne JCM, Testai E. Congeners-Specific Intestinal Absorption Of Microcystins In An In Vitro 3D Human Intestinal Epithelium: The Role Of Influx/Efflux Transporters. Front Toxicol 2022;4. [DOI: 10.3389/ftox.2022.883063] [Reference Citation Analysis]
3 Han H, Akiyoshi T, Morita T, Kataoka H, Katayama K, Yajima K, Imaoka A, Ohtani H. Comparison of the transport kinetics of fexofenadine and its pH dependency among OATP1A2 genetic variants. Drug Metabolism and Pharmacokinetics 2022. [DOI: 10.1016/j.dmpk.2022.100470] [Reference Citation Analysis]
4 Zakaria M, Hassan T, Fawzy A, Fathy M, Abdelazeem M, Magdy Abdelnour H, Abdelstar E, Nafea A, Ali AA. Association between ATP binding cassette gene member 1 polymorphism and glucocorticoid response in children with immune thrombocytopenia. Medicine (Baltimore) 2022;101:e29894. [PMID: 35839018 DOI: 10.1097/MD.0000000000029894] [Reference Citation Analysis]
5 Ménochet K, Chanteux H, Henshall J, Nicolas J, Wright S, Asperen J, Ungell A. Intestinal Epithelium and Drug Transporters. Oral Drug Delivery for Modified Release Formulations 2022. [DOI: 10.1002/9781119772729.ch3] [Reference Citation Analysis]
6 Abd El-Aziz NM, Khalifa I, Darwish AMG, Badr AN, Aljumayi H, Hafez ES, Shehata MG. Docking Analysis of Some Bioactive Compounds from Traditional Plants against SARS-CoV-2 Target Proteins. Molecules 2022;27:2662. [PMID: 35566014 DOI: 10.3390/molecules27092662] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Tirona RG, Kim RB. ORGANIC ANION TRANSPORTING POLYPEPTIDES OATP. Drug Transporters 2022. [DOI: 10.1002/9781119739883.ch5] [Reference Citation Analysis]
8 Oswald S. DRUG TRANSPORTERS IN THE HUMAN INTESTINE. Drug Transporters 2022. [DOI: 10.1002/9781119739883.ch16] [Reference Citation Analysis]
9 Chu X, Chan GH, Houle R, Lin M, Yabut J, Fandozzi C. In Vitro Assessment of Transporter Mediated Perpetrator DDIs for Several Hepatitis C Virus Direct-Acting Antiviral Drugs and Prediction of DDIs with Statins Using Static Models. AAPS J 2022;24. [DOI: 10.1208/s12248-021-00677-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Morita T, Akiyoshi T, Tsuchitani T, Kataoka H, Araki N, Yajima K, Katayama K, Imaoka A, Ohtani H. Inhibitory Effects of Cranberry Juice and Its Components on Intestinal OATP1A2 and OATP2B1: Identification of Avicularin as a Novel Inhibitor. J Agric Food Chem 2022. [PMID: 35230114 DOI: 10.1021/acs.jafc.2c00065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Funai Y, Takemura M, Inoue K, Shirasaka Y. Effect of Ingested Fluid Volume and Solution Osmolality on Intestinal Drug Absorption: Impact on Drug Interaction with Beverages. Eur J Pharm Sci 2022;:106136. [PMID: 35121020 DOI: 10.1016/j.ejps.2022.106136] [Reference Citation Analysis]
12 Pfab C, Abgaryan A, Danzer B, Mourtada F, Ali W, Gessner A, El-Najjar N. Ceftazidime and cefepime antagonize 5-fluorouracil's effect in colon cancer cells. BMC Cancer 2022;22:125. [PMID: 35100987 DOI: 10.1186/s12885-021-09125-4] [Reference Citation Analysis]
13 Zhang L, Enogieru OJ, Yee SW, Huang S, Giacomini KM. Mechanisms and genetics of drug transport. Atkinson's Principles of Clinical Pharmacology 2022. [DOI: 10.1016/b978-0-12-819869-8.00010-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Samura M, Hirose N, Kurata T, Takada K, Nagumo F, Koshioka S, Ishii J, Uchida M, Inoue J, Enoki Y, Taguchi K, Higashita R, Kunika N, Tanikawa K, Matsumoto K. Identification of Risk Factors for Daptomycin-Associated Creatine Phosphokinase Elevation and Development of a Risk Prediction Model for Incidence Probability. Open Forum Infect Dis 2021;8:ofab568. [PMID: 34888403 DOI: 10.1093/ofid/ofab568] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Traccis F, Presciuttini R, Pani PP, Sinclair JMA, Leggio L, Agabio R. Alcohol-medication interactions: A systematic review and meta-analysis of placebo-controlled trials. Neurosci Biobehav Rev 2021;132:519-41. [PMID: 34826511 DOI: 10.1016/j.neubiorev.2021.11.019] [Reference Citation Analysis]
16 Sato R, Akiyoshi T, Morita T, Katayama K, Yajima K, Kataoka H, Imaoka A, Ohtani H. Dual kinetics of OATP2B1: Inhibitory potency and pH-dependence of OATP2B1 inhibitors. Drug Metab Pharmacokinet 2021;41:100416. [PMID: 34619547 DOI: 10.1016/j.dmpk.2021.100416] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
17 Arian CM, Imaoka T, Yang J, Kelly EJ, Thummel KE. Gutsy science: In vitro systems of the human intestine to model oral drug disposition. Pharmacol Ther 2021;:107962. [PMID: 34478775 DOI: 10.1016/j.pharmthera.2021.107962] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Lei K, Yuan M, Zhou T, Ye Q, Zeng B, Zhou Q, Wei A, Guo L. Research progress in the application of bile acid-drug conjugates: A "trojan horse" strategy. Steroids 2021;173:108879. [PMID: 34181976 DOI: 10.1016/j.steroids.2021.108879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Wilson JL, Cheung KWK, Lin L, Green EAE, Porrás AI, Zou L, Mukanga D, Akpa PA, Darko DM, Yuan R, Ding S, Johnson WCN, Lee HA, Cooke E, Peck CC, Kern SE, Hartman D, Hayashi Y, Marks PW, Altman RB, Lumpkin MM, Giacomini KM, Blaschke TF. Scientific considerations for global drug development. Sci Transl Med 2020;12:eaax2550. [PMID: 32727913 DOI: 10.1126/scitranslmed.aax2550] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
20 Takeda F, Oda M, Terasaki M, Kubota A, Asada K, Ichimura Y, Kojima H, Saitoh H. Downregulated expression of organic anion transporting polypeptide (Oatp) 2b1 in the small intestine of rats with acute kidney injury. Drug Metab Pharmacokinet 2021;40:100411. [PMID: 34284282 DOI: 10.1016/j.dmpk.2021.100411] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Pangeni R, Kang S, Jha SK, Subedi L, Park JW. Intestinal membrane transporter-mediated approaches to improve oral drug delivery. J Pharm Investig 2021;51:137-58. [DOI: 10.1007/s40005-021-00515-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
22 Rysz J, Franczyk B, Kujawski K, Sacewicz-Hofman I, Ciałkowska-Rysz A, Gluba-Brzózka A. Are Nutraceuticals Beneficial in Chronic Kidney Disease? Pharmaceutics 2021;13:231. [PMID: 33562154 DOI: 10.3390/pharmaceutics13020231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Telbisz Á, Ambrus C, Mózner O, Szabó E, Várady G, Bakos É, Sarkadi B, Özvegy-Laczka C. Interactions of Potential Anti-COVID-19 Compounds with Multispecific ABC and OATP Drug Transporters. Pharmaceutics 2021;13:81. [PMID: 33435273 DOI: 10.3390/pharmaceutics13010081] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 20.0] [Reference Citation Analysis]
24 Hutchison LC. Pharmacology of Aging. Geriatric Gastroenterology 2021. [DOI: 10.1007/978-3-030-30192-7_11] [Reference Citation Analysis]
25 Vimalavathini R, Shri Hari Subhashri R, Kavimani S. Herb-Drug Interactions. Evidence Based Validation of Traditional Medicines 2021. [DOI: 10.1007/978-981-15-8127-4_31] [Reference Citation Analysis]
26 Choi YH, Chin YW. Multifaceted Factors Causing Conflicting Outcomes in Herb-Drug Interactions. Pharmaceutics 2020;13:43. [PMID: 33396770 DOI: 10.3390/pharmaceutics13010043] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
27 Samuels N, Ben-Arye E. Exploring Herbal Medicine Use during Palliative Cancer Care: The Integrative Physician as a Facilitator of Pharmacist-Patient-Oncologist Communication. Pharmaceuticals (Basel) 2020;13:E455. [PMID: 33322582 DOI: 10.3390/ph13120455] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
28 Lautz LS, Jeddi MZ, Girolami F, Nebbia C, Dorne JLCM. Metabolism and pharmacokinetics of pharmaceuticals in cats (Felix sylvestris catus) and implications for the risk assessment of feed additives and contaminants. Toxicol Lett 2021;338:114-27. [PMID: 33253781 DOI: 10.1016/j.toxlet.2020.11.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
29 Telbisz Á, Ambrus C, Mózner O, Szabó E, Várady G, Bakos É, Sarkadi B, Özvegy-laczka C. Interactions of anti-COVID-19 drug candidates with multispecific ABC and OATP drug transporters.. [DOI: 10.1101/2020.11.21.392555] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Morita T, Akiyoshi T, Sato R, Uekusa Y, Katayama K, Yajima K, Imaoka A, Sugimoto Y, Kiuchi F, Ohtani H. Citrus Fruit-Derived Flavanone Glycoside Narirutin is a Novel Potent Inhibitor of Organic Anion-Transporting Polypeptides. J Agric Food Chem 2020;68:14182-91. [DOI: 10.1021/acs.jafc.0c06132] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
31 Tikkanen A, Pierrot E, Deng F, Sánchez VB, Hagström M, Koenderink JB, Kidron H. Food Additives as Inhibitors of Intestinal Drug Transporter OATP2B1. Mol Pharm 2020;17:3748-58. [PMID: 32845645 DOI: 10.1021/acs.molpharmaceut.0c00507] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
32 Bakos É, Tusnády GE, Német O, Patik I, Magyar C, Németh K, Kele P, Özvegy-Laczka C. Synergistic transport of a fluorescent coumarin probe marks coumarins as pharmacological modulators of Organic anion-transporting polypeptide, OATP3A1. Biochem Pharmacol 2020;182:114250. [PMID: 32991865 DOI: 10.1016/j.bcp.2020.114250] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
33 Yao HT, Hsu YR, Li ML. Beverage-Drug Interaction: Effects of Green Tea Beverage Consumption on Atorvastatin Metabolism and Membrane Transporters in the Small Intestine and Liver of Rats. Membranes (Basel) 2020;10:E233. [PMID: 32937767 DOI: 10.3390/membranes10090233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
34 Arnold YE, Kalia YN. Using Ex Vivo Porcine Jejunum to Identify Membrane Transporter Substrates: A Screening Tool for Early-Stage Drug Development. Biomedicines 2020;8:E340. [PMID: 32927779 DOI: 10.3390/biomedicines8090340] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
35 van Nuland M, Rosing H, Huitema ADR, Beijnen JH. Predictive Value of Microdose Pharmacokinetics. Clin Pharmacokinet 2019;58:1221-36. [PMID: 31030372 DOI: 10.1007/s40262-019-00769-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
36 Sodhi JK, Benet LZ. The Necessity of Using Changes in Absorption Time to Implicate Intestinal Transporter Involvement in Oral Drug-Drug Interactions. AAPS J 2020;22:111. [PMID: 32808084 DOI: 10.1208/s12248-020-00469-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
37 Brecht K, Schäfer AM, Meyer Zu Schwabedissen HE. Uptake Transporters of the SLC21, SLC22A, and SLC15A Families in Anticancer Therapy-Modulators of Cellular Entry or Pharmacokinetics? Cancers (Basel) 2020;12:E2263. [PMID: 32806706 DOI: 10.3390/cancers12082263] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
38 Mohos V, Fliszár-Nyúl E, Ungvári O, Kuffa K, Needs PW, Kroon PA, Telbisz Á, Özvegy-Laczka C, Poór M. Inhibitory Effects of Quercetin and Its Main Methyl, Sulfate, and Glucuronic Acid Conjugates on Cytochrome P450 Enzymes, and on OATP, BCRP and MRP2 Transporters. Nutrients 2020;12:E2306. [PMID: 32751996 DOI: 10.3390/nu12082306] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 14.5] [Reference Citation Analysis]
39 Unger MS, Schumacher L, Enzlein T, Weigt D, Zamek-gliszczynski MJ, Schwab M, Nies AT, Drewes G, Schulz S, Reinhard FBM, Hopf C. Direct Automated MALDI Mass Spectrometry Analysis of Cellular Transporter Function: Inhibition of OATP2B1 Uptake by 294 Drugs. Anal Chem 2020;92:11851-9. [DOI: 10.1021/acs.analchem.0c02186] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
40 Lofthouse EM, Cleal JK, Hudson G, Lewis RM, Sengers BG. Glibenclamide transfer across the perfused human placenta is determined by albumin binding not transporter activity. Eur J Pharm Sci 2020;152:105436. [PMID: 32592753 DOI: 10.1016/j.ejps.2020.105436] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Ahn JH, Kim J, Rehman NU, Kim HJ, Ahn MJ, Chung HJ. Effect of Rumex Acetosa Extract, a Herbal Drug, on the Absorption of Fexofenadine. Pharmaceutics 2020;12:E547. [PMID: 32545588 DOI: 10.3390/pharmaceutics12060547] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
42 Kawasaki T, Shiozaki Y, Nomura N, Kawai K, Uwai Y, Nabekura T. Investigation of Fluorescent Substrates and Substrate-Dependent Interactions of a Drug Transporter Organic Anion Transporting Polypeptide 2B1 (OATP2B1). Pharm Res 2020;37:115. [PMID: 32483763 DOI: 10.1007/s11095-020-02831-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
43 Ogura J, Yamaguchi H, Mano N. Stimulatory effect on the transport mediated by organic anion transporting polypeptide 2B1. Asian J Pharm Sci 2020;15:181-91. [PMID: 32373198 DOI: 10.1016/j.ajps.2019.10.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
44 Morita T, Akiyoshi T, Sato R, Katayama K, Yajima K, Kataoka H, Imaoka A, Sugimoto Y, Ohtani H. pH-dependent transport kinetics of the human organic anion-transporting polypeptide 1A2. Drug Metabolism and Pharmacokinetics 2020;35:220-7. [DOI: 10.1016/j.dmpk.2019.12.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
45 Shi J, Sun C, Huang H, Lin W, Gao J, Lin Y, Zhang Z, Huo X, Tian X, Yu Z, Zhang B, Ma X. β-Glucuronidase- and OATP2B1-mediated drug interaction of scutellarin in Dengzhan Xixin Injection: A formulation aspect. Drug Dev Res 2020;81:609-19. [PMID: 32220026 DOI: 10.1002/ddr.21661] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
46 Tolentino-Hernández SJ, Cruz-Antonio L, Pérez-Urizar J, Cabrera-Fuentes HA, Castañeda-Hernández G. Oral Ciprofloxacin Pharmacokinetics in Healthy Mexican Volunteers and Other Populations: Is There Interethnic Variability? Arch Med Res 2020;51:268-77. [PMID: 32143939 DOI: 10.1016/j.arcmed.2020.02.008] [Reference Citation Analysis]
47 Peng Y, Chen L, Ye S, Kang Y, Liu J, Zeng S, Yu L. Research and development of drug delivery systems based on drug transporter and nano-formulation. Asian J Pharm Sci 2020;15:220-36. [PMID: 32373201 DOI: 10.1016/j.ajps.2020.02.004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 22.0] [Reference Citation Analysis]
48 Helal NA, Eassa HA, Amer AM, Eltokhy MA, Edafiogho I, Nounou MI. Nutraceuticals' Novel Formulations: The Good, the Bad, the Unknown and Patents Involved. Recent Pat Drug Deliv Formul 2019;13:105-56. [PMID: 31577201 DOI: 10.2174/1872211313666190503112040] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 26.5] [Reference Citation Analysis]
49 Hutchison LC. Pharmacology of Aging. Geriatric Gastroenterology 2020. [DOI: 10.1007/978-3-319-90761-1_11-1] [Reference Citation Analysis]
50 Bakos É, Német O, Patik I, Kucsma N, Várady G, Szakács G, Özvegy‐laczka C. A novel fluorescence‐based functional assay for human OATP1A2 and OATP1C1 identifies interaction between third‐generation P‐gp inhibitors and OATP1A2. FEBS J 2020;287:2468-85. [DOI: 10.1111/febs.15156] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
51 Li Y, Meng Q, Yang M, Liu D, Hou X, Tang L, Wang X, Lyu Y, Chen X, Liu K, Yu AM, Zuo Z, Bi H. Current trends in drug metabolism and pharmacokinetics. Acta Pharm Sin B 2019;9:1113-44. [PMID: 31867160 DOI: 10.1016/j.apsb.2019.10.001] [Cited by in Crossref: 66] [Cited by in F6Publishing: 74] [Article Influence: 22.0] [Reference Citation Analysis]
52 Martinec O, Huliciak M, Staud F, Cecka F, Vokral I, Cerveny L. Anti-HIV and Anti-Hepatitis C Virus Drugs Inhibit P-Glycoprotein Efflux Activity in Caco-2 Cells and Precision-Cut Rat and Human Intestinal Slices. Antimicrob Agents Chemother 2019;63:e00910-19. [PMID: 31481446 DOI: 10.1128/AAC.00910-19] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
53 Xue Y, Ma C, Hanna I, Pan G. Intestinal Transporter-Associated Drug Absorption and Toxicity. In: Liu X, Pan G, editors. Drug Transporters in Drug Disposition, Effects and Toxicity. Singapore: Springer; 2019. pp. 361-405. [DOI: 10.1007/978-981-13-7647-4_8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
54 Costache II, Miron A, Hăncianu M, Aursulesei V, Costache AD, Aprotosoaie AC. Pharmacokinetic Interactions between Cardiovascular Medicines and Plant Products. Cardiovasc Ther 2019;2019:9402781. [PMID: 32089733 DOI: 10.1155/2019/9402781] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
55 Kawanishi T, Arakawa H, Masuo Y, Nakamichi N, Kato Y. Bile Duct Obstruction Leads to Increased Intestinal Expression of Breast Cancer Resistance Protein With Reduced Gastrointestinal Absorption of Imatinib. Journal of Pharmaceutical Sciences 2019;108:3130-7. [DOI: 10.1016/j.xphs.2019.05.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
56 Medwid S, Li MM, Knauer MJ, Lin K, Mansell SE, Schmerk CL, Zhu C, Griffin KE, Yousif MD, Dresser GK, Schwarz UI, Kim RB, Tirona RG. Fexofenadine and Rosuvastatin Pharmacokinetics in Mice with Targeted Disruption of Organic Anion Transporting Polypeptide 2B1. Drug Metab Dispos 2019;47:832-42. [DOI: 10.1124/dmd.119.087619] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 9.3] [Reference Citation Analysis]
57 Klietz M, Greten S, Wegner F, Höglinger GU. Safety and Tolerability of Pharmacotherapies for Parkinson’s Disease in Geriatric Patients. Drugs Aging 2019;36:511-30. [DOI: 10.1007/s40266-019-00654-z] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
58 McFeely SJ, Ritchie TK, Yu J, Nordmark A, Levy RH, Ragueneau-Majlessi I. Identification and Evaluation of Clinical Substrates of Organic Anion Transporting Polypeptides 1B1 and 1B3. Clin Transl Sci 2019;12:379-87. [PMID: 30706983 DOI: 10.1111/cts.12623] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
59 Windt T, Tóth S, Patik I, Sessler J, Kucsma N, Szepesi Á, Zdrazil B, Özvegy-Laczka C, Szakács G. Identification of anticancer OATP2B1 substrates by an in vitro triple-fluorescence-based cytotoxicity screen. Arch Toxicol 2019;93:953-64. [PMID: 30863990 DOI: 10.1007/s00204-019-02417-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
60 Oswald S. Organic Anion Transporting Polypeptide (OATP) transporter expression, localization and function in the human intestine. Pharmacology & Therapeutics 2019;195:39-53. [DOI: 10.1016/j.pharmthera.2018.10.007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 9.7] [Reference Citation Analysis]
61 Drozdzik M, Busch D, Lapczuk J, Müller J, Ostrowski M, Kurzawski M, Oswald S. Protein Abundance of Clinically Relevant Drug Transporters in the Human Liver and Intestine: A Comparative Analysis in Paired Tissue Specimens. Clin Pharmacol Ther 2019;105:1204-12. [PMID: 30447067 DOI: 10.1002/cpt.1301] [Cited by in Crossref: 71] [Cited by in F6Publishing: 73] [Article Influence: 23.7] [Reference Citation Analysis]
62 Funai Y, Shirasaka Y, Ishihara M, Takemura M, Ichijo K, Kishimoto H, Inoue K. Effect of Osmolality on the Pharmacokinetic Interaction between Apple Juice and Atenolol in Rats. Drug Metab Dispos 2019;47:386-91. [DOI: 10.1124/dmd.118.084483] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
63 Quignot N, Wiecek W, Amzal B, Dorne J. The Yin–Yang of CYP3A4: a Bayesian meta-analysis to quantify inhibition and induction of CYP3A4 metabolism in humans and refine uncertainty factors for mixture risk assessment. Arch Toxicol 2019;93:107-19. [DOI: 10.1007/s00204-018-2325-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
64 Tod M, Goutelle S, Bleyzac N, Bourguignon L. A Generic Model for Quantitative Prediction of Interactions Mediated by Efflux Transporters and Cytochromes: Application to P-Glycoprotein and Cytochrome 3A4. Clin Pharmacokinet 2019;58:503-23. [DOI: 10.1007/s40262-018-0711-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
65 Li Y, Ning J, Wang Y, Wang C, Sun C, Huo X, Yu Z, Feng L, Zhang B, Tian X, Ma X. Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicology Letters 2018;294:27-36. [DOI: 10.1016/j.toxlet.2018.05.008] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 8.5] [Reference Citation Analysis]
66 Zamek-Gliszczynski MJ, Taub ME, Chothe PP, Chu X, Giacomini KM, Kim RB, Ray AS, Stocker SL, Unadkat JD, Wittwer MB, Xia C, Yee SW, Zhang L, Zhang Y; International Transporter Consortium. Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance. Clin Pharmacol Ther 2018;104:890-9. [PMID: 30091177 DOI: 10.1002/cpt.1112] [Cited by in Crossref: 137] [Cited by in F6Publishing: 140] [Article Influence: 34.3] [Reference Citation Analysis]
67 Tian DD, Kellogg JJ, Okut N, Oberlies NH, Cech NB, Shen DD, McCune JS, Paine MF. Identification of Intestinal UDP-Glucuronosyltransferase Inhibitors in Green Tea (Camellia sinensis) Using a Biochemometric Approach: Application to Raloxifene as a Test Drug via In Vitro to In Vivo Extrapolation. Drug Metab Dispos 2018;46:552-60. [PMID: 29467215 DOI: 10.1124/dmd.117.079491] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
68 Grimstein M, Huang SM. A regulatory science viewpoint on botanical-drug interactions. J Food Drug Anal 2018;26:S12-25. [PMID: 29703380 DOI: 10.1016/j.jfda.2018.01.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
69 Patik I, Székely V, Német O, Szepesi Á, Kucsma N, Várady G, Szakács G, Bakos É, Özvegy-Laczka C. Identification of novel cell-impermeant fluorescent substrates for testing the function and drug interaction of Organic Anion-Transporting Polypeptides, OATP1B1/1B3 and 2B1. Sci Rep 2018;8:2630. [PMID: 29422623 DOI: 10.1038/s41598-018-20815-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 7.3] [Reference Citation Analysis]
70 Grimm M, Koziolek M, Saleh M, Schneider F, Garbacz G, Kühn J, Weitschies W. Gastric Emptying and Small Bowel Water Content after Administration of Grapefruit Juice Compared to Water and Isocaloric Solutions of Glucose and Fructose: A Four-Way Crossover MRI Pilot Study in Healthy Subjects. Mol Pharmaceutics 2018;15:548-59. [DOI: 10.1021/acs.molpharmaceut.7b00919] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 11.0] [Reference Citation Analysis]
71 Morival C, Westerlynck R, Bouzillé G, Cuggia M, Le Corre P. Prevalence and nature of statin drug-drug interactions in a university hospital by electronic health record mining. Eur J Clin Pharmacol 2018;74:525-34. [DOI: 10.1007/s00228-017-2400-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
72 Hijazi S, Obeid N, Jabri R. On Drug Dosage Control Using Description Defeasible Logic. 2017 International Conference on Computational Science and Computational Intelligence (CSCI) 2017. [DOI: 10.1109/csci.2017.288] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
73 Miners JO, Yang X, Knights KM, Zhang L. The Role of the Kidney in Drug Elimination: Transport, Metabolism, and the Impact of Kidney Disease on Drug Clearance. Clin Pharmacol Ther 2017;102:436-49. [PMID: 28599065 DOI: 10.1002/cpt.757] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 9.4] [Reference Citation Analysis]